A new approach, published in “Cell Reports,” to regenerate inner ear sensory hair cells is said to lay the groundwork for treating chronic noise-induced hearing loss by the company, Frequency Therapeutics, and its co-founders who are drawing on research from Brigham and Women's Hospital (BWH), Harvard Medical School, Mass Eye and Ear Infirmary, and MIT. The program is expected to progress to into human clinical trials within the next 18 months.
Experts in the field of audiology gathered to discuss the latest technology and design, as well as future methods for treating hearing loss. Participants now have access to the training resources and learning materials for the next 90 days.
“This paper outlines the first global consensus on how we can optimize care for adults with severe to profound hearing loss. The recommendations for surgeons, audiology experts, and healthcare providers are crystal clear,” said Dr Craig Buchman.
On August 20, 2020, the Company received a letter from Nasdaq stating that because the Company’s shares had a closing bid price at or above $1.00 per share for a minimum of ten (10) consecutive business days, the Company’s stock had regained compliance with the Minimum Bid Price Requirement for continued listing on Nasdaq, and that the matter is now closed.